China SXT Pharmaceuticals (SXTC) Short term Debt (2018 - 2025)

China SXT Pharmaceuticals' Short term Debt history runs 8 years deep, the most recent figure standing at $4475.0 for Q3 2025.

• In Q3 2025, Short term Debt fell 50.72% year-over-year to $4475.0; the TTM figure through Sep 2025 stood at $4475.0 (down 50.72% YoY), while the FY2025 annual figure was $8781.0, down 98.22% from the prior year.
• Short term Debt was $4475.0 for Q3 2025 at China SXT Pharmaceuticals, down from $8781.0 in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $12.1 million in Q1 2021 to a low of $4475.0 in Q3 2025.
• Historically, Short term Debt has averaged $1.6 million across 5 years, with a median of $93595.0 in 2023.
• The sharpest annual moves came in 2021 and 2022: Short term Debt surged 4527.81% in 2021, then slumped 99.91% in 2022.
• A 5-year view of Short term Debt shows it stood at $2.1 million in 2021, then sank by 43.04% to $1.2 million in 2022, then plunged by 98.36% to $19737.0 in 2023, then sank by 54.0% to $9080.0 in 2024, then plunged by 50.72% to $4475.0 in 2025.
• The last three Short term Debt figures came in at $4475.0 (Q3 2025), $8781.0 (Q1 2025), and $9080.0 (Q3 2024), per Business Quant data.